Type 2a usher syndrome9/8/2023 ![]() ![]() 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 37.108090000623 proteins and genes Proteins 0.000 claims description 41.102000004169 proteins and genes Human genes 0.000 claims description 41.102000007260 Deoxyribonuclease I Human genes 0.000 claims description 43.108010008532 Deoxyribonuclease I Proteins 0.000 claims description 43.230000014509 gene expression Effects 0.000 claims description 70.108010042407 Endonucleases Proteins 0.000 claims description 73.229920001850 Nucleic acid sequence Polymers 0.000 claims description 79.239000002157 polynucleotide Substances 0.000 claims description 81.229920000023 polynucleotide Polymers 0.000 claims description 81.241000432074 Adeno-associated virus Species 0.000 claims description 88.229920003013 deoxyribonucleic acid Polymers 0.000 claims description 109.108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims description 113.150000007523 nucleic acids Chemical group 0.000 claims description 162.125000003729 nucleotide group Chemical group 0.000 claims description 166.230000001225 therapeutic Effects 0.000 claims abstract description 25.230000035772 mutation Effects 0.000 claims abstract description 378.102100014983 USH2A Human genes 0.000 claims abstract description 397.239000000463 material Substances 0.000 title abstract description 18.201000008579 Usher syndrome type 2A Diseases 0.000 title claims abstract description 459.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201762609333P external-priority Application filed by Casebia Therapeutics Llp filed Critical Casebia Therapeutics Llp Priority to JP2020534230A priority Critical patent/JP2021508451A/en Priority to CN201880089894.2A priority patent/CN111836892A/en Priority to AU2018393050A priority patent/AU2018393050A1/en Priority to CA3084632A priority patent/CA3084632A1/en Priority to EP18842660.5A priority patent/EP3728594A1/en Publication of WO2019123429A1 publication Critical patent/WO2019123429A1/en Priority to US16/905,145 priority patent/US11072792B2/en Priority to US17/360,578 priority patent/US20210403905A1/en Links Inventor Albena Kantardzhieva Akiko Noma Abraham Scaria Original Assignee Casebia Therapeutics Llp Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2019123429A1 - Materials and methods for treatment of usher syndrome type 2a WO2019123429A1 - Materials and methods for treatment of usher syndrome type 2a ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |